Signal Transduction and Targeted Therapy · 18 Nov 2026
Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours
Stein-Erik Gullaksenh-index 10, Mathias Brevik, Erin Craig, Monica Hellesøy, Øystein Sefland, Ulla Olsson-Strömberg, Jesper Stentoft, Johan Richter, Tobias Gedde-Dahl, Robert Tibshirani, Sylvia K. Plevritis, Dominik Wolf, Satu Mustjoki, Henrik Hjorth-Hansen, Bjørn Tore Gjertsenh-index 53
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Chronic myeloid leukemia (CML) is effectively treated with small molecule BCR::ABL1 tyrosine kinase inhibitors (TKIs) but as in all cancers, early identification of suboptimal responders and non-responders is a challenge. Through mass cytometry analysis of peripheral blood leukocytes collected on the first day of TKI treatment, we generated high-dimensional single-cell data from de novo chronic phase CML patients enrolled in two multicenter clinical trials (clinicaltrials.gov: NCT01725204 and NCT01061177). In leukocytes, dasatinib and nilotinib inhibited intracellular signaling within 1 or 3 h after first oral dose, respectively, and each TKI had a unique signaling signature reflecting its kinase specificity profile beyond BCR::ABL1. From these data, an immune and signaling profile was constructed for each patient that predicted the treatment response (BCR::ABL1 IS , %) during the first 12 months of treatment. The predictive features were drug specific: response to dasatinib was dominated by leukemic burden, neutrophil maturity (pSTAT3 Y705) and immune effector activity (pERK ½ in T- and NK cells), whereas response to nilotinib was driven by the intrinsic signaling states of CD34 + CD38 low CD25 + LSC-like cells (cleaved caspase-3, pCRKL Y207 and STAT3 [total and Y705]). These results show that single cell immune and signaling profiles measured within hours of first dose can predict 12-month treatment response, anticipating future optimization of kinase inhibitor treatment within days rather than months.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Bjørn Tore Gjertsen has the highest h-index among the authors (53).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (90)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 70 more references
A free account opens the rest of the citing papers and references on every paper’s page.